Abstract. The prognosis of patients with esophageal cancer remains poor. TNM classification is not sufficient to predict their prognosis, and novel predictive markers of the prognosis of esophageal cancer patients are therefore needed. Poly A binding protein, cytoplasmic 1 (PABPC1) plays a role in post-transcriptional control of mRNA and may be involved in tumorigenesis. PABPC1 expression has not been studied in esophageal cancer. Expression of PABPC1 was quantified by real-time reverse transcription polymerase chain reaction (RT-PCR) using LightCycler in 41 primary esophageal squamous cell carcinomas (ESCCs) and their paired normal esophageal mucosa. We examined the correlation between PABPC1 expression and the clinicopathological factors and prognosis of ESCC patients. Reduced expression of PABPC1 was accompanied by locally invasive tumors (t-factor, p=0.0145) and more advanced tumors (pathologic stage, p=0.0264). Moreover, ESCC patients with low PABPC1 mRNA expression had a significantly shorter postoperative survival time than those with high expression (median survival, 3.1 vs. 6.5 months, p=0.002). In esophageal cancer, reduced expression of PABPC1 was correlated with local tumor progression and poor prognosis after surgery.
Introduction
Esophageal cancer is the sixth most common cancer in the world, of which esophageal squamous cell carcinoma (ESCC) accounts for >90% of cases. The prognosis of patients with esophageal cancer remains poor, prompting the search for new treatment strategies. Today, the overall 5-year survival rate is generally less than 50%, despite the use of multi-modality therapy. Even in early stage disease, many patients develop local tumor recurrence or distant metastasis within a short time after surgery. To develop a strategy for new treatment, it is important to understand the biological behavior of esophageal cancer. Previous studies revealed that several genes and molecules are involved in the origin and/or progression of esophageal cancer, including TP53 (1), deleted in esophageal cancer 1 (DEC1) (2) , deleted in colorectal cancer (DCC) (3) , deleted in lung cancer 1 (DLC1) (4) , cyclin D1 (5), transforming growth factor-beta receptor type II (TGFBRII) (6) , adenomatous polyposis coli (APC) (7) , survivin (8) , and murine double minute 2 (MDM2) (9) . However, the precise mechanisms that underlie the development and progression of ESCC are unclear.
The mRNA degradation mechanism plays an important role in controlling gene expression. Any alteration to the control of mRNA degradation will have a significant effect on cell growth control, as evidenced by the observation that overexpression of eIF-4 transforms cells (10) , and expression of a dominant-negative mutant of the double-stranded RNAdependent kinase, which phosphorylates eIF-2 (11), causes noncancerous cells to become tumorigenic (12) .
PABPC1 mRNA is known to be involved in mRNA translation and degradation (13, 14) , and stabilizes the 5' cap of mRNA. In addition, PABPC1 plays the most important role in deadenylation and protects poly (A) tail by covering the poly (A) tail. However, in yeast, it is known that depletion of the poly (A) binding protein results in the inhibition of translation initiation and poly (A) shortening (15) . Poly (A) binding protein has shown to be involved in ribonuclease activity for the poly (A) tail, thus conferring PABPC1 with apparently contradictory functions of protection and degradation of the poly (A) tail (16) . In this study, we report the correlation between PABPC1 expression and the clinicopathological factors and prognosis of ESCC patients.
Materials and methods
Tissue samples. Samples were obtained from 41 esophageal cancer patients who had undergone surgery at the Second Department Surgery, Nagoya City University Medical School between 1996 and 2000 without pre-operative chemotherapy or radiation.
The tumors were classified according to the guidelines for the clinical and pathological studies on carcinoma of the esophagus (17) . All samples for RT-PCR were immediately frozen in liquid nitrogen and stored at -80˚C until analysis. The samples were used with written consent from the patients. The details of the 41 patients with PABPC1 are shown Table I .
RNA extraction and RT-PCR analysis.
Total RNA was extracted from the esophageal cancer tissues, and normal esophageal mucosa samples were taken as far from the tumor as possible using the Absolutely RNA™ RT-PCR Miniprep kit (Stratagene, La Jolla, CA). The concentration of total RNA was adjusted to 200 ng/ml using a spectrophotometer. Reverse transcriptional reaction was carried out at 42˚C for 90 min and 95˚C for 5 min followed by incubation at 72˚C for 15 min using 10 μg total RNA, 0.5 mg oligo (dT) primer, and Superscript II enzyme (Gibco BRL, Gaithersburg, MD). To confirm the accuracy of RNA extraction and RT-PCR, all samples were subjected to PCR amplification using the Light Table I . PABPC1 mRNA expression and clinical characteristics of 41 patients with esophageal carcinoma. 
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Cycler-FastStart DNA Master SYBR-Green kit (Roche Molecular Biochemicals, Mannheim, Germany). Primer sequences for the PABPC1 gene were: forward, 5-AGCAAA TGTTGGGTGAACGG-3; and reverse, 5-ACCGGTGGC ACTGTTAACTG-3. PCR protocol was initial denaturation at 95˚C for 10 min, followed by 50 cycles at 95˚C for 15 sec, annealing at 60˚C for 5 sec, and extension at 72˚C for 10 sec. The PCR product was quantified with the intensity of SYBRGreen I at 88˚C.
Statistical analysis. Data are expressed as the mean ± standard deviation. Statistical analysis was carried out using StatView software (Abacus Concepts, Berkeley, CA), and the Kruskal-Wallis and Mann-Whitney U tests were used to evaluate the significance of the difference in expression of PABPC1 mRNA. The survival of PABPC1 patients after surgery was examined by the Kaplan-Meier method, and the difference in the survival was analyzed using the log-rank test. A p-value <0.05 was considered to be statistically significant.
Results
We examined the PABPC1 mRNA expression level in 41 primary esophageal cancer tissues and their paired normal esophageal tissues using LightCycler. PABPC1 mRNA expression was detectable in the majority of ESCC samples and all samples of normal esophageal mucosa. PABPC1 expression was standardized in reference to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). PABPC1 expression in the tumor varied, and there was no significant difference between PABPC1 expression of the tumor and corresponding normal esophageal mucosa (data not shown). PABPC1 expression in ESCC tissue was significantly correlated with tumor size and local invasiveness (t-factor) (Fig. 1) . PABPC1 expression was significantly reduced in locally advanced ESCC (t3 and t4 tumors, p=0.0145) (Fig. 1) . The levels of PABPC1 expression were significantly lower in stages 0-2 ESCC than in stage 3/4 ESCC (p=0.0264) (Fig. 2) . PABPC1 expression levels in 
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patients with ESCC who had lymphatic invasion were significantly lower compared with the expression levels in patients without lymphatic invasion (p=0.0022). PABPC1 expression levels in ESCC patients with vein invasion were significantly lower compared with the expression levels in patients without vein invasion (p=0.0299). PABPC1 expression did not have an apparent correlation with lymph node metastasis (n-factor) (Table II) . According to other clinical factors, including the gender and age of ESCC patients, no apparent differences in PABPC1 expression were recognized (Table II) .
We also investigated the correlation between the PABPC1 expression and survival time of the ESCC patients after surgery with a mean follow-up of 14.6 months. We divided the 41 ESCC patients into two groups. Group A contained patients with high expression of PABPC1 [tumor to normal ratio (T:N ratio) >1.4, n=17], and group B had patients with low expression (T:N ratio <1.4, n=24). Patients with low PABPC1 expression had a significantly shorter median survival time (3.117±1.667 months) after surgery than those with high PABPC1 expression (6.502±4.014 months) (p=0.002; logrank test) (Fig. 3) .
Discussion
Poly A binding protein, cytoplasmic 1 (PABPC1), which is found complexed to the 3-prime poly (A) tail of eukaryotic mRNA, is required for poly (A) shortening and translation initiation (13) . PABPC1 participates in at least three major post-transcriptional events: i) mRNA biogenesis; ii) regulation of mRNA turnover; and iii) initiation of protein synthesis (18) . However, exact reasons for the essential role of the PABPC1 function remain to be elucidated.
PABPC1 is the key factor responsible for the poly (A) tailstimulated pathway of translational initiation (18, 19 (20) .
In this study, we reported that decreased expression of PABPC1 in esophageal cancer tissue is accompanied by the local progression of esophageal cancer (Figs. 1 and 2 and Table II) . Patients with lower PABPC1 expression also had a poorer prognosis (Fig. 3) . Thus, the down-regulation of PABPC1 may contribute to tumor growth in esophageal carcinoma by losing normal control of mRNA turnover. Because PABPC1 plays critical roles in translation and mRNA stabilization/degradation, it is necessary to investigate how the deficiency of normal mRNA regulation by down-regulation of PABPC1 mRNA might result in tumor progression and poor prognosis.
PABPC1 is located at chromosome region 8q22.2-23. Loss of heterozygosity (LOH) at 8q22 has been reported in human malignancies, such as oral cancer (21), breast cancer (22) and leukemia (23) , and proposes the existence of a tumor suppressor gene in various cancers. It is speculated that the inactivation of PABPC1 may be involved in the carcinogenesis of those organs. In esophageal cancer, we are currently investigating LOH at 8q22 (unpublished data) as a possible mechanism of PABPC1 inactivation. Although we have not examined the mutations of PABPC1, PABPC1 may be a tumor suppressor. In addition to genetic changes, transcriptional silencing due to methylation in the promoter region may be responsible for the down-regulation of PABPC1. This possibility remains to be examined.
In esophageal cancer patients, many prognostic markers such as cyclin D1, E-cadherin and MDM2 have been reported (5, 9) . We have also reported that the expression of survivin (8) , pituitary tumor transforming gene 1 (PTTG1) (24) , peroxisome proliferator-activated receptor gamma (PPARÁ) (25) , DNA fragmentation factor 45 (DFF45) (26) , and excision repair cross complementing 3 (ERCC3) (27) may be prognostic markers of ESCC. PABPC1 has now been added as a possible prognostic indicator in ESCC patients.
Although the precise molecular mechanism of downregulated PABPC1 expression needs to be clarified, our data indicate that PABPC1 may be a good molecular prognostic marker, as well as a molecular target for development of an effective drug for patients with esophageal cancer. Elucidating the function of PABPC1 may lead to a better understanding of the carcinogenic mechanism of tumor progression in patients with esophageal carcinoma. There is a significant difference between the two groups (p=0.002; log-rank test).
